menu
    • menu
    [{"orgOrder":0,"company":"Saptagir Laboratories","sponsor":"Jubilant Generics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Saptagir Labs Signs Manufacturing Deal with Jubilant Generics for Remdesivir","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"","productType":"Small molecule","productStatus":"Approved","date":"September 2020","year":"2020","type":"Agreement","leadProduct":"Remdesivir","moa":"RdRp","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Saptagir Laboratories","amount2":0,"therapeuticAreaNew":"Infections and Infectious Diseases","highestDevelopmentStatusNew":"Approved","highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","productSubType":"Small molecule","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Saptagir Laboratories \/ Jubilant Generics","highestDevelopmentStatusID":"12","companyTruncated":"Saptagir Laboratories \/ Jubilant Generics"}]

    Find Clinical Drug Pipeline Developments & Deals by Saptagir Laboratories

    Menu

    Saptagir Laboratories

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Saptagir Laboratories

                            India arrow
                            Discovery on Target
                            Not Confirmed

                            Saptagir Laboratories

                            India arrow
                            Discovery on Target
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Sponsor : Jubilant Generics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Saptagir Labs Signs Manufacturing Deal with Jubilant Generics for Remdesivir

                            Details : Under the terms of the agreement, Remdesivir will be produced at Saptagir Laboratories' Hyderabad WHO GMP certified sterile drug product manufacturing plant.

                            Brand Name : Undisclosed

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 14, 2020

                            Lead Product(s) : Remdesivir

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Sponsor : Jubilant Generics

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth